
Actavis gains new Allergan directors
pharmafile | March 20, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Actavis, Allergan, Michael Gallagher, Peter McDonnellÂ
Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of directors, which follows on from the firms merger last year.
Gallagher (pictured) was elected to the Allergan board back in 1998 and served as its lead independent director and chair of the organisation and compensation committee. In 2004 he retired as chief executive and as a director of Playtex Products.
McDonnell was appointed to Allergan’s board in 2013, and served on the corporate governance and compliance committee and the science and technology committee. He has also been the chief medical editor of Ophthalmology Times since 2004, and on the editorial boards of numerous ophthalmology journals.
“The addition of Michael and Peter brings significant experience from Allergan to our board, and I welcome their insights and expertise as we combine our two dynamic organisations,” says Brent Saunders, chief executive and president of Actavis.
David Pyott, chairman and chief executive of Allergan, has elected not to join the combined company’s board, but will continue to serve as chairman of The Allergan Foundation, a US-based private charity.
Related Content

FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …

$63bn Allergan/AbbVie merger review could be delayed by coronavirus
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …

Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
New Phase 3 data has been released showing that both 50mg and 100mg doses of …






